FDA adcomm votes in favor of approving Provention Bio’s drug to delay type 1 diabetes

Following heated discussions on the small but positive pivotal trial, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Thursday voted 10-7 in favor of the FDA approving Provention Bio’s teplizumab for the delay of clinical type 1 diabetes in at-risk individuals.